Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
LTGO · Why this verdict
Why Latigo Biotherapeutics (LTGO) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.3/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Latigo shows bullish insider buying and a large theoretical gap to its analyst target, but value-trap signals from margin compression and negative free cash flow keep the business quality below the engine's floor, arguing for exiting rather than holding.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The engine flags 2 of 5 value-trap signals for Latigo: operating margin compression to -49.5% and negative free cash flow. Bear case | Operating margin should improve toward breakeven and free cash flow should turn less negative over the next 12 months. | ↓Deteriorating |
| CounterA clinical-stage biotech with a -49.5% operating margin is normal pre-commercialization burn, not necessarily evidence of a value trap in the traditional sense. | ||
Latigo's quality score of 3.3 sits below the engine's 4.0 minimum floor. Warnings | The quality score should rise above the 4.0 floor over the next 12 months. | ↓Deteriorating |
| CounterA single composite quality score can understate a clinical-stage biotech whose real value driver is pipeline data, not current financial metrics. | ||
Insiders bought a net of 280,000 shares over the past 90 days across 2 buy transactions with zero sells, and the engine classifies the insider signal as bullish. Insider | Insider buying activity should continue or at least remain net positive over the next 12 months. | →Stable |
| CounterA couple of insider buy transactions on a small biotech can be a modest personal-portfolio decision rather than a strong conviction signal about undisclosed positive data. | ||
Latigo trades 92.8% below its analyst price target, one of the largest gaps in the dataset, with the value dimension flagged as attractively valued. Estimated upside | The stock should close a meaningful portion of the 92.8% gap toward the analyst target over the next 12 months if clinical catalysts play out. | ↓Deteriorating |
| CounterLight analyst coverage (only 4 analysts) on a speculative biotech can make an implied 92.8% gap unreliable, reflecting stale or overly optimistic targets rather than achievable upside. | ||
The engine flags 2 of 5 value-trap signals for Latigo: operating margin compression to -49.5% and negative free cash flow.
↓DeterioratingBear case
- Expectation
- Operating margin should improve toward breakeven and free cash flow should turn less negative over the next 12 months.
CounterA clinical-stage biotech with a -49.5% operating margin is normal pre-commercialization burn, not necessarily evidence of a value trap in the traditional sense.
Latigo's quality score of 3.3 sits below the engine's 4.0 minimum floor.
↓DeterioratingWarnings
- Expectation
- The quality score should rise above the 4.0 floor over the next 12 months.
CounterA single composite quality score can understate a clinical-stage biotech whose real value driver is pipeline data, not current financial metrics.
Insiders bought a net of 280,000 shares over the past 90 days across 2 buy transactions with zero sells, and the engine classifies the insider signal as bullish.
→StableInsider
- Expectation
- Insider buying activity should continue or at least remain net positive over the next 12 months.
CounterA couple of insider buy transactions on a small biotech can be a modest personal-portfolio decision rather than a strong conviction signal about undisclosed positive data.
Latigo trades 92.8% below its analyst price target, one of the largest gaps in the dataset, with the value dimension flagged as attractively valued.
↓DeterioratingEstimated upside
- Expectation
- The stock should close a meaningful portion of the 92.8% gap toward the analyst target over the next 12 months if clinical catalysts play out.
CounterLight analyst coverage (only 4 analysts) on a speculative biotech can make an implied 92.8% gap unreliable, reflecting stale or overly optimistic targets rather than achievable upside.
Per-dimension breakdown
Quality
1.4/10data confidence 86%| Component | Sub-score |
|---|---|
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 4.4 |
| Moat | 4.0 |
| Piotroski F | 0.0 |
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 0/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
4.4/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 1.4 |
| OBV | 10.0 |
| MA position | 3.5 |
| Volume | 2.5 |
- ▸Volume accumulation (rising OBV)
Sentiment
8.4/10data confidence 67%| Component | Sub-score |
|---|---|
| Analyst rating | 7.1 |
| Price target | 10.0 |
- ▸Light analyst coverage (4.0) — signal dampened
- ▸Analyst upside: 136%
Insider
8.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 8.0 |
| insider conviction | 8.0 |
- ▸Notable insider buying — $5,040,000 (0.343% of mkt cap)
Peer rank
3.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.0 |
| growth rank | 5.0 |
Technical
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 5.0 |
| support resistance | 5.1 |
| 52w position | 7.1 |
| gap | 5.0 |
Risk (lower is worse)
4.2/10data confidence 60%| Component | Sub-score |
|---|---|
| days to cover | 10.0 |
| volatility | 0.0 |
| debt equity | 2.5 |
Catalyst
1.7/10data confidence 75%| Component | Sub-score |
|---|---|
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (7)
- ASYMMETRY:6.7>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:60d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:4.4<4.5
Warning (0)
none
Reward-to-Risk
6.70
Upside
+100.5%
Downside
15.0%
Sizing output
AVOID
SetupRange Bound — RSI 49 mid-range, Bollinger mid-band
EdgeInst Constrain — Small cap ($1.5B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 4.4<4.5 outcome against Value at 9.0 and asymmetric R:R of 6.70.
The strongest dimensions are Value at 9.0, Sentiment at 8.4, and Insider at 8.0; the weakest are Quality at 1.4, Catalyst at 1.7, and Peer rank at 3.8. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 6.70 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Value Trap Margin Compression
Trip ifOperating margin rises above -20% from the current -49.5%.
- P2Quality Below Floor
Trip ifQuality score rises above 4.0 from the current 3.3.
- P3Bullish Insider Buying
Trip ifNet insider activity turns negative, with insiders selling more than 100,000 net shares over 90 days.
- P4Large Gap To Analyst Target
Trip ifThe gap to the analyst target compresses below 50%, from the current 92.8%.